Mirum Pharmaceuticals Gets Positive CHMP Opinion For LIVMARLI Oral Solution For The Treatment Of PFIC In Patients 3-Months Or Older
Portfolio Pulse from Benzinga Newsdesk
Mirum Pharmaceuticals (NASDAQ:MIRM) received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) for its drug LIVMARLI for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients three months and older. The decision is based on a Phase 3 study showing significant reduction in pruritus severity. A decision by the European Commission is expected in Q3 2024.
May 31, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mirum Pharmaceuticals received a positive CHMP opinion for LIVMARLI, indicating significant clinical benefits for PFIC patients. This could lead to European Commission approval in Q3 2024.
The positive CHMP opinion is a strong indicator of potential European Commission approval, which would expand the market for LIVMARLI. The Phase 3 study results showing significant efficacy further bolster the drug's prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100